Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reiterated by equities research analysts at Robert W. Baird in a research report issued on Monday. They presently have a $102.00 price target on the stock. Robert W. Baird’s price objective would suggest a potential upside of 76.20% from the stock’s previous close.

SRPT has been the topic of a number of other research reports. JMP Securities raised Sarepta Therapeutics to an “outperform” rating and lifted their target price for the company from $10.00 to $60.00 in a research report on Monday, September 19th. Royal Bank Of Canada raised Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $83.00 target price on the stock in a research report on Monday, September 19th. Cowen and Company reaffirmed an “outperform” rating and issued a $64.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, October 5th. Leerink Swann reaffirmed an “underperform” rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, August 4th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, July 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $58.44.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 1.52% during trading on Monday, hitting $57.01. The stock had a trading volume of 653,633 shares. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The stock’s 50-day moving average is $40.98 and its 200-day moving average is $25.39. The stock’s market capitalization is $2.73 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter last year, the business earned ($0.87) earnings per share. Analysts predict that Sarepta Therapeutics will post ($4.23) EPS for the current fiscal year.

In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 40,179 shares of the business’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $2,410,740.00. Following the completion of the transaction, the chief executive officer now directly owns 117,162 shares in the company, valued at $7,029,720. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Jayant Aphale sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at $1,074,500. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in SRPT. National Planning Corp increased its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares in the last quarter. Rhumbline Advisers increased its position in shares of Sarepta Therapeutics by 1.6% in the second quarter. Rhumbline Advisers now owns 46,719 shares of the company’s stock valued at $891,000 after buying an additional 721 shares in the last quarter. Teacher Retirement System of Texas increased its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares in the last quarter. First Allied Advisory Services Inc. increased its position in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares in the last quarter. Finally, LGL Partners LLC increased its position in shares of Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock valued at $485,000 after buying an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.